Clinical Trial

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation

MOA: Rezatapopt (PC14586) is a p53 reactivator that selectively binds to the mutated p53 Y220C protein and restores p53 WT activity.

Key Eligibility

• Histologically or cytologically confirmed locally advanced or
  metastatic solid tumor with TP53 Y220C mutation
• Patients must have tried standard treatments for their cancer and
  shown progression or be deemed ineligible for standard care by the
  investigator
  • Patients with CRPC must have ongoing androgen
    deprivation therapy with a gonadotropin-releasing hormone
    analog or inhibitor, or orchiectomy
  • Patients with ovarian cancer must have platinum-resistant
    disease or platinum-refractory disease
• Patient with a known KRAS mutation, defined as a single
  nucleotide variant (SNV) are excluded